Allergan (AGN) Receives FDA Approval for TRIVARIS(TM) 80/mg/mL
More News related to AGN
- Biotech Takeover Buzz Hot and Heavy After ImClone Offer (ONXX, OSIP, BIIB, AMLN, XPNT, CYPB, ISPH)
- Allergan (AGN) Reports In-Line Q2 EPS of $0.63; Guides Q3/FY08; Declares Qtr. Dividend of $0.05/Share
- Allergan Reports Second Quarter 2008 Operating Results
- Citi Adds Kohl's (KSS) and Nike (NKE) to Recommended List; Removes NWS, MRO and AGN
- AEGON Releases EUR 315 Million of Capital Through Securitization
More News related to FDA
- Orthofix International (OFIX) Receives FDA 510(k) Approval
- Rosetta Genomics (ROSG) Identifies Potential microRNA Biomarkers in Blood Serum
- BioCryst Pharma (BCRX) Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis
- Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
- GTC Biotherapeutics (GTCB) Granted Priority Review from the FDA
Allergan, Inc. (NYSE: AGN) today announced that the U.S. FDA has approved TRIVARIS(TM) 80 mg/mL, a synthetic glucocorticoid corticosteroid with anti-inflammatory action. Delivered via intravitreal injection, the ophthalmic indications for TRIVARIS(TM) include sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. These are inflammatory conditions that can result in vision loss.
Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide.
Related Categories
FDAStocks Mentioned
-0.71Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
